Taichung, Taiwan

Der-Yang Cho

USPTO Granted Patents = 15 

 

Average Co-Inventor Count = 5.8

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2018-2025

Loading Chart...
Loading Chart...
15 patents (USPTO):

Title: The Innovative Journey of Der-Yang Cho: Pioneering Immunomodulation in Taichung

Introduction: Der-Yang Cho, a prolific inventor based in Taichung, Taiwan, has left an indelible mark in the field of immunomodulation and anti-tumor research. With a total of 10 patents under his belt, Cho's groundbreaking work continues to revolutionize the medical landscape.

Latest Patents: Among his latest patents is the "Display screen or portion thereof with graphical user interface" and the groundbreaking "Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same." This patent focuses on a nanobody that specifically binds to human leukocyte antigen-G, programmed cell death ligand 1, and CD3 ε for treating cancer and immune-related disorders.

Career Highlights: Der-Yang Cho has made significant contributions during his tenure at institutions such as China Medical University Hospital and China Medical University. His innovative research and patented inventions have propelled advancements in the field of immunomodulation, earning him recognition as a key figure in the industry.

Collaborations: Throughout his career, Cho has collaborated with esteemed colleagues such as Shao-Chih Chiu and Chih-Ming Pan. Together, they have worked tirelessly to drive innovation, foster new ideas, and bring revolutionary concepts to life in the realm of medical research.

Conclusion: Der-Yang Cho's dedication to pioneering advancements in immunomodulation and anti-tumor therapies showcases his unwavering commitment to improving healthcare outcomes. His profound impact on the field serves as a testament to his ingenuity and unwavering pursuit of excellence in the realm of medical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…